Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Operating Expenses (2020 - 2025)

Lyell Immunopharma's Operating Expenses history spans 6 years, with the latest figure at $37.3 million for Q3 2025.

  • For Q3 2025, Operating Expenses fell 26.26% year-over-year to $37.3 million; the TTM value through Sep 2025 reached $342.9 million, up 57.91%, while the annual FY2024 figure was $358.8 million, 45.19% up from the prior year.
  • Operating Expenses for Q3 2025 was $37.3 million at Lyell Immunopharma, down from $47.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $201.2 million in Q4 2024 and bottomed at $37.3 million in Q3 2025.
  • The 5-year median for Operating Expenses is $59.1 million (2023), against an average of $65.5 million.
  • The largest annual shift saw Operating Expenses plummeted 38.18% in 2021 before it surged 237.96% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $50.4 million in 2021, then increased by 25.44% to $63.2 million in 2022, then dropped by 5.78% to $59.5 million in 2023, then soared by 237.96% to $201.2 million in 2024, then plummeted by 81.47% to $37.3 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Operating Expenses are $37.3 million (Q3 2025), $47.1 million (Q2 2025), and $57.4 million (Q1 2025).